European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]

ELOS is a prospective, randomized, open-label, controlled, two-armed parallel group, phase II multicentre trial in local advanced stage III, IVA/B head and neck squamous cell carcinoma of the larynx or hypopharynx (LHNSCC) with PD-L1-expression within tumor tissue biopsy, calculated as CPS ≥ 1 curable by total laryngectomy. Induction chemotherapy (IC) with Docetaxel and Cisplatin (TP) followed by radiation will be compared to additional PD-1 inhibition. Patients will be selected after short induction early response evaluation after the first cycle IC (IC-1) aiming on larynx organ-preservation

Trial Details

NCT ID
NCT06137378
Phase
PHASE2
Sponsor
University of Leipzig
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • KEYTRUDA®
Locations (sample)
  • Mannheim, Baden-Würtemberg, Germany|49.4891,8.46694
  • Ulm, Baden-Würtemberg, Germany|48.39841,9.99155
  • München, Bavaria, Germany|48.69668,13.46314
  • Regensburg, Bavaria, Germany|49.01513,12.10161
  • Würzburg, Bavaria, Germany|49.79391,9.95121

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Male and female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of squ…
  • Stage III, IVA or IVB, whenever clear resection margins R0 \>5 mm can be achieved and no radiologic signs of extranodal extension of neck nodes are…
  • Have provided newly obtained excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →